On Jan. 23, 2020, two independent meningitis B studies were published in the New England Journal of Medicine demonstrated the real-world impact of GSK’s Bexsero vaccine in reducing disease in infants and underscore the need for individual protection among adolescents.

According to Public Health England, over a three-year period the total number of meningitis B cases dropped 75 percent.